Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 2/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.62 |
| ▸ | CNR2 | P34972 | 16/20 | 0.60 |
| ▸ | CNR1 | P21554 | 7/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13714236 | 1.00 | NPY1R (0.62) | NPY1RNPY5RCNR2CNR1MEN1 | |
| SCHEMBL5315881 | 0.89 | NPY1R (0.61) | NPY1RNPY5RCNR2CNR1 | |
| SCHEMBL4616421 | 0.85 | SFRP1 (0.56) | CNR2CNR1MEN1ALDH1A1CYP2C9 | |
| SCHEMBL4616423 | 0.85 | SFRP1 (0.56) | CNR2CNR1MEN1ALDH1A1CYP2C9 | |
| SCHEMBL5848417 | 0.84 | MEN1 (0.57) | NPY5RCNR2CNR1MEN1ALDH1A1 | |
| SCHEMBL5849554 | 0.84 | MEN1 (0.57) | NPY5RCNR2CNR1MEN1ALDH1A1 | |
| SCHEMBL27917798 | 0.83 | NPY1R (0.57) | NPY1RNPY5RCNR2CNR1MEN1 | |
| SCHEMBL13796004 | 0.81 | NPY1R (0.62) | NPY1RNPY5RCNR2CNR1 | |
| SCHEMBL13714075 | 0.80 | MEN1 (0.63) | NPY1RNPY5RMEN1ALDH1A1KMT2A | |
| SCHEMBL3852957 | 0.80 | MEN1 (0.63) | NPY1RNPY5RMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579504-B2 | ABCA1 elevating compounds | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070203245-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007067817-A1 | ABCA1 ELEVATING COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203245-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | NPY1R 4624/4885NPY5R 4392/4885CNR2 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.